Lifecore Biomedical, Inc.
$5.35
0%
2026-04-21 07:52:00
www.lifecore.com
NMS: LFCR
Explore Lifecore Biomedical, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$200.6 M
Current Price
$5.35
52W High / Low
$8.98 / $3.62
Stock P/E
—
Book Value
$-0.38
Dividend Yield
—
ROCE
-5.74%
ROE
-612.08%
Face Value
—
EPS
$-1.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
400
Beta
0.88
Debt / Equity
414.8
Current Ratio
3.49
Quick Ratio
2.26
Forward P/E
-5.72
Price / Sales
1.38
Enterprise Value
$350.09 M
EV / EBITDA
42.48
EV / Revenue
2.7
Rating
None
Target Price
$6.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
| 2. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 3. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
| 4. | Indivior Pharmaceuticals, Inc. | $32.42 | 31.62 | $3.95 B | — | 92.33% | -96.33% | $38 / $8.69 | $-0.78 |
| 5. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 6. | PRF Technologies Ltd. | $2.64 | — | $2.31 M | — | -53.59% | -90.37% | $17.95 / $1.8 | $10.29 |
| 7. | Journey Medical Corporation | $5.19 | — | $147.31 M | — | -14.3% | -44.03% | $9.55 / $4.31 | $1.17 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 31.11 M | 36.44 M | 35.15 M | 32.56 M | 24.7 M |
| Operating Profit | -3.07 M | 2.9 M | -2.29 M | -1.96 M | -11.58 M |
| Net Profit | -9.99 M | -1.15 M | -14.77 M | -6.57 M | -16.23 M |
| EPS in Rs | -0.27 | -0.03 | -0.39 | -0.18 | -0.43 |
Profit & Loss
Figures shown in M / B
| 2025 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Sales | — | 128.87 M | 128.26 M | 103.27 M |
| Operating Profit | — | -12.01 M | -7.19 M | -19.72 M |
| Net Profit | — | -38.72 M | 12.01 M | -99.56 M |
| EPS in Rs | — | -1.03 | 0.32 | -2.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Total Assets | 232.18 M | 239.34 M | 253.96 M | 253.54 M |
| Total Liabilities | 246.38 M | 238.01 M | 242.65 M | 257.77 M |
| Equity | -14.2 M | 1.34 M | 11.31 M | -4.23 M |
| Current Assets | 82.29 M | 85.68 M | 81.03 M | 93.88 M |
| Current Liabilities | 23.57 M | 30.18 M | 38.87 M | 39.29 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -0.21 M | 0.26 M | -17.44 M | -22.59 M |
| Investing CF | -6.42 M | -18.39 M | -4.81 M | 79.96 M |
| Financing CF | 6.42 M | 7.51 M | 39.7 M | -57.02 M |
| Free CF | -13.62 M | -18.14 M | -38.92 M | -52.53 M |
| Capex | -13.41 M | -18.39 M | -21.48 M | -29.94 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 24.2% | -7.19% | — | — |
| Earnings Growth % | 112.07% | 14.7% | — | — |
| Profit Margin % | 9.37% | -96.41% | -104.89% | — |
| Operating Margin % | -5.6% | -19.1% | -3.08% | — |
| Gross Margin % | 32.63% | 27.1% | 35.11% | — |
| EBITDA Margin % | 27.77% | -32.12% | 11.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.